Mallinckrodt plc

Track this case

Case Number:

1:20-bk-12522

Court:

Delaware

Nature of Suit:

Firms

Companies

Government Agencies

Sectors & Industries:

November 18, 2021
Mallinckrodt Ch. 11 Plan Hearing Won't Restart Monday

The Delaware bankruptcy judge overseeing Mallinckrodt's Chapter 11 case Thursday granted requests to delay the resumption of the drugmaker's plan confirmation hearing, saying he first needs to digest claims it engaged in drug price manipulation.
November 17, 2021
Mallinckrodt Denies Manipulating Acthar Market

Mallinckrodt closed its defense against claims it inflated the price of its Acthar gel on Wednesday, with witnesses saying that the drugmaker didn't suppress a competing product and that the speaking fees it paid to doctors didn't increase sales.
November 16, 2021
Mallinckrodt Says Insurers' Acthar Claims Off By $317M

An expert witness for Mallinckrodt told a Delaware bankruptcy judge Tuesday that two insurers seeking more than $317 million in damages wouldn't be owed any more than $2.6 million even if their claims that the drugmaker suppressed competition for its Acthar gel were true.
November 15, 2021
Mallinckrodt Exec Says Acthar Price Hikes Were Necessary

A Mallinckrodt executive defended the pricing and marketing of the drugmaker's Acthar gel on Monday as a pair of insurers presented a Delaware judge with the last of their evidence that Mallinckrodt engaged in a yearslong scheme to drive up Acthar's cost.
November 12, 2021
Insurers Say Mallinckrodt Sales Strategy Cost Them $320M

A pair of insurers seeking antitrust damages from drugmaker Mallinckrodt over the sales of its Acthar gel put their expert witnesses before a Delaware bankruptcy judge on Friday, claiming they overpaid more than $320 million for Acthar over the past year.
November 08, 2021
Insurers Claim Mallinckrodt Inflated Acthar Price By $300M

A pair of health insurers told a Delaware bankruptcy judge Monday that Mallinckrodt PLC owes them more than $300 million because of the drugmaker's alleged efforts to keep a cheaper alternative to its Acthar infantile spasm drug off the market.
November 05, 2021
Mallinckrodt Cleared On $94M Ch. 11 Bond Penalty

A Delaware bankruptcy judge on Friday found Mallinckrodt does not owe a $94 million payment to noteholders, saying the creditors should not get a "windfall" simply as a result of the drugmaker's Chapter 11 filing.
November 04, 2021
Mallinckrodt Can Duck Acthar Royalties In Chapter 11

A bankruptcy judge in Delaware Thursday ruled drugmaker Mallinckrodt can use Chapter 11 to escape royalty payments for the sale of its Acthar Gel medication as the confirmation hearing for the company's restructuring plan continued.
November 02, 2021
Antitrust Group Says Mallinckrodt Plan Lacks Sufficient Votes

A group with antitrust claims against drugmaker Mallinckrodt challenged the vote approving the company's Chapter 11 plan on Tuesday, but lost a bid to get counsel for the unsecured creditors on the stand to address the vote solicitation process.
October 15, 2021
Mallinckrodt Ch.11 Plan Under Fire From Multiple Angles

The drugmaker Mallinckrodt is facing more than a dozen objections to its proposed reorganization plan as it heads for a confirmation hearing in a Delaware bankruptcy court in just over two weeks, on grounds ranging from liability releases to insurance claims to bond terms.